PMID- 36695327
OWN - NLM
STAT- MEDLINE
DCOM- 20230126
LR  - 20230202
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Print)
IS  - 0886-022X (Linking)
VI  - 45
IP  - 1
DP  - 2023 Dec
TI  - Expression of urinary exosomal miRNA-615-3p and miRNA-3147 in diabetic kidney 
      disease and their association with inflammation and fibrosis.
PG  - 2121929
LID - 10.1080/0886022X.2022.2121929 [doi]
LID - 2121929
AB  - BACKGROUND: Diabetic kidney disease (DKD) is one of the most common chronic 
      complications of type 2 diabetes mellitus (T2DM), and it is particularly 
      important to identify a high-quality method for evaluating disease progression. 
      Urinary exosomes contain microRNA that might promise early diagnostic and 
      monitoring markers of DKD. The present study aimed to identify novel 
      exosome-related markers associated with inflammation and fibrosis to assess the 
      progression of DKD. METHOD: Exosomes were extracted from the urine of 83 
      participants to determine the expression levels of miRNA-615-3p and miRNA-3147 in 
      20 healthy people, 21 patients with T2DM and 42 patients with DKD, as determined 
      by RT-qPCR. The circulating expression level of TGF-beta1 was detected by ELISA. 
      Serum Cystatin C was measured by a latex-enhanced immunoturbidimetric method. The 
      correlation analyses were performed for all clinical and laboratory parameters. 
      RESULT: The expression level of urinary exosomal miRNA-615-3p in DKD patients was 
      significantly higher than that in the control group and the T2DM group by 
      RT-qPCR. The expression of miRNA-3147 showed an upward trend in the three groups 
      of subjects, but it was not statistically significant. The urinary exosomal 
      miRNA-615-3p was positively correlated with serum Cystatin C, plasma TGF-beta1, 
      creatinine, BUN, PCR and 24-h urine protein, and negatively correlated with eGFR 
      and albumin. The diagnostic efficacy of urinary exosomal miRNA-615-3p combined 
      with the ACR was higher than that of ACR alone. CONCLUSIONS: Urinary exosomal 
      miRNA-615-3p may be used as a novel biomarker for evaluating the progression of 
      DKD, and may be involved in the process of inflammation and fibrosis in DKD. The 
      combined diagnosis of urinary exosomal miRNA-615-3p and ACR may be used as more 
      stable and sensitive diagnostic criteria for DKD.
FAU - Wang, Jiaxin
AU  - Wang J
AD  - Department of Nephrology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Tao, Yiying
AU  - Tao Y
AD  - Department of Nephrology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Zhao, Fan
AU  - Zhao F
AD  - Department of Nephrology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Liu, Tong
AU  - Liu T
AD  - Department of Nephrology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Shen, Xiahong
AU  - Shen X
AD  - Department of Nephrology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Zhou, Ling
AU  - Zhou L
AD  - Department of Nephrology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (MicroRNAs)
RN  - 0 (Cystatin C)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *MicroRNAs/urine
MH  - *Diabetic Nephropathies
MH  - Cystatin C
MH  - Transforming Growth Factor beta1
MH  - *Diabetes Mellitus, Type 2
MH  - Biomarkers
MH  - Inflammation
MH  - Fibrosis
PMC - PMC9879181
OTO - NOTNLM
OT  - Exosomes
OT  - diabetic kidney disease
OT  - inflammation and fibrosis
OT  - microRNA
COIS- The authors have no conflicts of interest to declare.
EDAT- 2023/01/26 06:00
MHDA- 2023/01/27 06:00
PMCR- 2023/01/25
CRDT- 2023/01/25 06:12
PHST- 2023/01/25 06:12 [entrez]
PHST- 2023/01/26 06:00 [pubmed]
PHST- 2023/01/27 06:00 [medline]
PHST- 2023/01/25 00:00 [pmc-release]
AID - 2121929 [pii]
AID - 10.1080/0886022X.2022.2121929 [doi]
PST - ppublish
SO  - Ren Fail. 2023 Dec;45(1):2121929. doi: 10.1080/0886022X.2022.2121929.